Go Pro
→ Forget the million-dollar nest egg — you only need THIS much (From Investors Alley) (Ad)tc pixel Free LNSR Stock Alerts

LENSAR (LNSR) Competitors

LENSAR logo
$6.04 0.00 (0.00%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$6.05 +0.01 (+0.17%)
As of 08/7/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

LNSR vs. OBIO, CNXU, FOCL, SENS, and PDEX

Should you buy LENSAR stock or one of its competitors? MarketBeat compares LENSAR with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LENSAR include Orchestra BioMed (OBIO), Conexeu Sciences (CNXU), FocalTherics (FOCL), Senseonics Holdings, Inc. Common Stock (SENS), and Pro-Dex (PDEX). These companies are all part of the "healthcare equipment" industry.

How does LENSAR compare to Orchestra BioMed?

Orchestra BioMed (NASDAQ:OBIO) and LENSAR (NASDAQ:LNSR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Orchestra BioMed currently has a consensus target price of $13.60, indicating a potential upside of 220.75%. LENSAR has a consensus target price of $10.00, indicating a potential upside of 65.56%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, equities analysts plainly believe Orchestra BioMed is more favorable than LENSAR.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Orchestra BioMed
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
LENSAR
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

LENSAR has higher revenue and earnings than Orchestra BioMed. LENSAR is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Orchestra BioMed$33.48M7.58-$52.70M-$0.97N/A
LENSAR$58.44M1.27-$34.28M-$0.58N/A

In the previous week, Orchestra BioMed had 4 more articles in the media than LENSAR. MarketBeat recorded 5 mentions for Orchestra BioMed and 1 mentions for LENSAR. Orchestra BioMed's average media sentiment score of 0.32 beat LENSAR's score of 0.00 indicating that Orchestra BioMed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Orchestra BioMed
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
LENSAR
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

53.2% of Orchestra BioMed shares are owned by institutional investors. Comparatively, 40.2% of LENSAR shares are owned by institutional investors. 7.5% of Orchestra BioMed shares are owned by company insiders. Comparatively, 65.8% of LENSAR shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Orchestra BioMed has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market. Comparatively, LENSAR has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

LENSAR has a net margin of 50.94% compared to Orchestra BioMed's net margin of -166.96%. Orchestra BioMed's return on equity of -157.46% beat LENSAR's return on equity.

Company Net Margins Return on Equity Return on Assets
Orchestra BioMed-166.96% -157.46% -60.18%
LENSAR 50.94%-183.19%42.26%

Summary

Orchestra BioMed beats LENSAR on 9 of the 16 factors compared between the two stocks.

How does LENSAR compare to Conexeu Sciences?

Conexeu Sciences (NASDAQ:CNXU) and LENSAR (NASDAQ:LNSR) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

Conexeu Sciences presently has a consensus price target of $20.00, suggesting a potential upside of 147.83%. LENSAR has a consensus price target of $10.00, suggesting a potential upside of 65.56%. Given Conexeu Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Conexeu Sciences is more favorable than LENSAR.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Conexeu Sciences
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
LENSAR
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Conexeu Sciences has higher earnings, but lower revenue than LENSAR. Conexeu Sciences is trading at a lower price-to-earnings ratio than LENSAR, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Conexeu SciencesN/AN/A-$3.92M-$0.11N/A
LENSAR$58.44M1.27-$34.28M-$0.58N/A

LENSAR has a net margin of 50.94% compared to Conexeu Sciences' net margin of 0.00%. Conexeu Sciences' return on equity of 0.00% beat LENSAR's return on equity.

Company Net Margins Return on Equity Return on Assets
Conexeu SciencesN/A N/A N/A
LENSAR 50.94%-183.19%42.26%

40.2% of LENSAR shares are held by institutional investors. 65.8% of LENSAR shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Conexeu Sciences and Conexeu Sciences both had 1 articles in the media. Conexeu Sciences' average media sentiment score of 0.00 equaled LENSAR'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Conexeu Sciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
LENSAR
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

LENSAR beats Conexeu Sciences on 7 of the 12 factors compared between the two stocks.

How does LENSAR compare to FocalTherics?

FocalTherics (NASDAQ:FOCL) and LENSAR (NASDAQ:LNSR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

FocalTherics has higher revenue and earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FocalTherics$70.53M3.31-$29.25M-$0.81N/A
LENSAR$58.44M1.27-$34.28M-$0.58N/A

62.7% of FocalTherics shares are owned by institutional investors. Comparatively, 40.2% of LENSAR shares are owned by institutional investors. 10.1% of FocalTherics shares are owned by company insiders. Comparatively, 65.8% of LENSAR shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

LENSAR has a net margin of 50.94% compared to FocalTherics' net margin of -41.47%. FocalTherics' return on equity of -137.61% beat LENSAR's return on equity.

Company Net Margins Return on Equity Return on Assets
FocalTherics-41.47% -137.61% -40.62%
LENSAR 50.94%-183.19%42.26%

FocalTherics has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market. Comparatively, LENSAR has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market.

FocalTherics currently has a consensus target price of $9.00, suggesting a potential upside of 44.69%. LENSAR has a consensus target price of $10.00, suggesting a potential upside of 65.56%. Given LENSAR's higher probable upside, analysts plainly believe LENSAR is more favorable than FocalTherics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FocalTherics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50
LENSAR
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, LENSAR had 1 more articles in the media than FocalTherics. MarketBeat recorded 1 mentions for LENSAR and 0 mentions for FocalTherics. FocalTherics' average media sentiment score of 1.00 beat LENSAR's score of 0.00 indicating that FocalTherics is being referred to more favorably in the media.

Company Overall Sentiment
FocalTherics Positive
LENSAR Neutral

Summary

FocalTherics beats LENSAR on 9 of the 17 factors compared between the two stocks.

How does LENSAR compare to Senseonics Holdings, Inc. Common Stock?

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) and LENSAR (NASDAQ:LNSR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Senseonics Holdings, Inc. Common Stock presently has a consensus price target of $17.20, suggesting a potential upside of 145.01%. LENSAR has a consensus price target of $10.00, suggesting a potential upside of 65.56%. Given Senseonics Holdings, Inc. Common Stock's stronger consensus rating and higher possible upside, equities analysts clearly believe Senseonics Holdings, Inc. Common Stock is more favorable than LENSAR.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Senseonics Holdings, Inc. Common Stock
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
LENSAR
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

LENSAR has a net margin of 50.94% compared to Senseonics Holdings, Inc. Common Stock's net margin of -225.09%. Senseonics Holdings, Inc. Common Stock's return on equity of -165.80% beat LENSAR's return on equity.

Company Net Margins Return on Equity Return on Assets
Senseonics Holdings, Inc. Common Stock-225.09% -165.80% -80.14%
LENSAR 50.94%-183.19%42.26%

In the previous week, Senseonics Holdings, Inc. Common Stock had 5 more articles in the media than LENSAR. MarketBeat recorded 6 mentions for Senseonics Holdings, Inc. Common Stock and 1 mentions for LENSAR. LENSAR's average media sentiment score of 0.00 beat Senseonics Holdings, Inc. Common Stock's score of -0.42 indicating that LENSAR is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Senseonics Holdings, Inc. Common Stock
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
LENSAR
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Senseonics Holdings, Inc. Common Stock has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market. Comparatively, LENSAR has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market.

LENSAR has higher revenue and earnings than Senseonics Holdings, Inc. Common Stock. LENSAR is trading at a lower price-to-earnings ratio than Senseonics Holdings, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Senseonics Holdings, Inc. Common Stock$35.26M8.32-$69.11M-$2.23N/A
LENSAR$58.44M1.27-$34.28M-$0.58N/A

12.4% of Senseonics Holdings, Inc. Common Stock shares are held by institutional investors. Comparatively, 40.2% of LENSAR shares are held by institutional investors. 4.7% of Senseonics Holdings, Inc. Common Stock shares are held by insiders. Comparatively, 65.8% of LENSAR shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Senseonics Holdings, Inc. Common Stock and LENSAR tied by winning 8 of the 16 factors compared between the two stocks.

How does LENSAR compare to Pro-Dex?

LENSAR (NASDAQ:LNSR) and Pro-Dex (NASDAQ:PDEX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

LENSAR has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, Pro-Dex has a beta of 0.02, meaning that its share price is 98% less volatile than the broader market.

LENSAR has a net margin of 50.94% compared to Pro-Dex's net margin of 16.08%. Pro-Dex's return on equity of 22.78% beat LENSAR's return on equity.

Company Net Margins Return on Equity Return on Assets
LENSAR50.94% -183.19% 42.26%
Pro-Dex 16.08%22.78%14.30%

40.2% of LENSAR shares are held by institutional investors. Comparatively, 15.3% of Pro-Dex shares are held by institutional investors. 65.8% of LENSAR shares are held by insiders. Comparatively, 45.9% of Pro-Dex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

LENSAR currently has a consensus target price of $10.00, suggesting a potential upside of 65.56%. Pro-Dex has a consensus target price of $70.00, suggesting a potential upside of 6.77%. Given LENSAR's higher probable upside, equities research analysts plainly believe LENSAR is more favorable than Pro-Dex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LENSAR
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Pro-Dex
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

In the previous week, Pro-Dex had 1 more articles in the media than LENSAR. MarketBeat recorded 2 mentions for Pro-Dex and 1 mentions for LENSAR. Pro-Dex's average media sentiment score of 0.34 beat LENSAR's score of 0.00 indicating that Pro-Dex is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LENSAR
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Pro-Dex
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Pro-Dex has higher revenue and earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LENSAR$58.44M1.27-$34.28M-$0.58N/A
Pro-Dex$66.59M3.14$8.98M$3.6218.11

Summary

Pro-Dex beats LENSAR on 9 of the 15 factors compared between the two stocks.

Get LENSAR News Delivered to You Automatically

Sign up to receive the latest news and ratings for LNSR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LNSR vs. The Competition

Export
MetricLENSARHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$74.17M$5.76B$7.00B$12.99B
Dividend YieldN/A1.78%2.58%10.20%
P/E Ratio-10.4124.27270.5925.05
Price / Sales1.2768.54598.0184.12
Price / CashN/A33.5528.8937.44
Price / Book-2.776.1111.386.43
Net Income-$34.28M$149.01M$3.45B$348.10M
7 Day Performance12.27%2.56%3.46%2.68%
1 Month Performance0.50%0.80%-0.66%-0.83%
1 Year Performance-53.07%4.94%77.38%23.97%

LENSAR Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LNSR
LENSAR
1.1132 of 5 stars		$6.04
flat		$10.00
+65.6%		-53.1%$74.17M$58.44MN/A110
OBIO
Orchestra BioMed
3.8713 of 5 stars		$4.27
flat		$13.60
+218.5%		+56.5%$255.69M$33.48MN/A4
CNXU
Conexeu Sciences
2.6088 of 5 stars		$9.28
+2.1%		$20.00
+115.6%		N/A$248.18MN/AN/A4
FOCL
FocalTherics
3.5952 of 5 stars		$6.34
flat		$9.00
+42.0%		N/A$237.62M$70.53MN/A230
SENS
Senseonics Holdings, Inc. Common Stock
2.4495 of 5 stars		$5.44
+0.7%		$17.20
+216.2%		N/A$227.35M$35.26MN/A90

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:LNSR) was last updated on 8/10/2026 by MarketBeat.com Staff.
From Our Partners
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump's Next Move Could Shrink Your Dollar
There's a plan in Washington being called the 'Mar-a-Lago Accord' - a deliberate strategy to weaken the U.S. d...
Priority Gold | Sponsoredtc pixel
I’ll Keep This Short… (Huge AI Opportunity)
Analyst Ross Givens says the top AI opportunity right now isn't Microsoft, Google, Amazon, Apple, or Nvidia - ...
Traders Agency | Sponsoredtc pixel
AI Bubble Could Finally Be Done - Wall St's Warning
Wall Street analysts are warning that the AI-driven market rally may be nearing its limits, with some cautioni...
TradeSmith | Sponsoredtc pixel
China is not hedging. It's escaping.
China's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...
Behind the Markets | Sponsoredtc pixel